Compare Ascendis Pharma A/S (ASND) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Starbucks Corp — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while Starbucks Corp trades at $107.66 (market cap $120.82B). The key difference: Starbucks Corp is far larger — about 6.8× Ascendis Pharma A/S's market cap, and Starbucks Corp pays a 2.34% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SBUX | |
|---|---|---|
Market Cap | $17.74B | $120.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $106.82 |
52-Week Low | $163.32 | $78.46 |
Enterprise Value | $18.11B | $143.51B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Starbucks (SBUX) trades at $106.01, down 0.38% today, with a bullish technical signal and recent earnings beat in Q1 2026. The company's revenue grew to $37.18B in 2025, though net income margin compressed to 3.89%. Recent news highlights AI initiatives to cut software costs, while analyst consensus is split evenly between Buy and Hold ratings with a $107.67 price target.
Outlook remains mixed: AI cost savings and loyalty growth offer upside, but margin pressure and high P/E of 80.92 pose risks. Near-term performance hinges on Q2 2026 earnings versus the $0.65 EPS estimate and execution of operational efficiencies amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
